Posted on

Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study

Agomab Therapeutics today announced positive results of the Phase 1 study of AGMB-447 in IPF patients.

Go to Source

By sf-admin